Correlation Between ATyr Pharma and Seres Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ATyr Pharma and Seres Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ATyr Pharma and Seres Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ATyr Pharma and Seres Therapeutics, you can compare the effects of market volatilities on ATyr Pharma and Seres Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ATyr Pharma with a short position of Seres Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ATyr Pharma and Seres Therapeutics.

Diversification Opportunities for ATyr Pharma and Seres Therapeutics

0.09
  Correlation Coefficient

Significant diversification

The 3 months correlation between ATyr and Seres is 0.09. Overlapping area represents the amount of risk that can be diversified away by holding ATyr Pharma and Seres Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Seres Therapeutics and ATyr Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ATyr Pharma are associated (or correlated) with Seres Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Seres Therapeutics has no effect on the direction of ATyr Pharma i.e., ATyr Pharma and Seres Therapeutics go up and down completely randomly.

Pair Corralation between ATyr Pharma and Seres Therapeutics

Given the investment horizon of 90 days ATyr Pharma is expected to under-perform the Seres Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, ATyr Pharma is 1.08 times less risky than Seres Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Seres Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  557.00  in Seres Therapeutics on August 31, 2024 and sell it today you would lose (465.00) from holding Seres Therapeutics or give up 83.48% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy69.8%
ValuesDaily Returns

ATyr Pharma  vs.  Seres Therapeutics

 Performance 
       Timeline  
ATyr Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ATyr Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, ATyr Pharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.
Seres Therapeutics 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Seres Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

ATyr Pharma and Seres Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ATyr Pharma and Seres Therapeutics

The main advantage of trading using opposite ATyr Pharma and Seres Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ATyr Pharma position performs unexpectedly, Seres Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will offset losses from the drop in Seres Therapeutics' long position.
The idea behind ATyr Pharma and Seres Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Complementary Tools

Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk